Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis.

[1]  S. Feske,et al.  Molecular regulation of CRAC channels and their role in lymphocyte function , 2013, Cellular and Molecular Life Sciences.

[2]  D. Conte,et al.  Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy , 2013, Inflammatory bowel diseases.

[3]  D. Strøbæk,et al.  NS6180, a new KCa3.1 channel inhibitor prevents T‐cell activation and inflammation in a rat model of inflammatory bowel disease , 2013, British journal of pharmacology.

[4]  D. Patel,et al.  Effect of IL-17A blockade with secukinumab in autoimmune diseases , 2012, Annals of the rheumatic diseases.

[5]  L. Conforti,et al.  KCa3.1 and TRPM7 Channels at the Uropod Regulate Migration of Activated Human T Cells , 2012, PloS one.

[6]  M. Neuman,et al.  Inflammatory bowel disease: role of diet, microbiota, life style. , 2012, Translational research : the journal of laboratory and clinical medicine.

[7]  K. Chandy,et al.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. , 2012, Toxicon : official journal of the International Society on Toxinology.

[8]  K. Maclennan,et al.  Potential role of reduced basolateral potassium (IKCa3.1) channel expression in the pathogenesis of diarrhoea in ulcerative colitis , 2012, The Journal of pathology.

[9]  G. Cui,et al.  TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. , 2011, Cytokine.

[10]  H. Wulff,et al.  The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression , 2011, Drug development research.

[11]  C. Fernández-Rodríguez,et al.  Environmental risk factors in inflammatory bowel diseases. Investigating the hygiene hypothesis: A Spanish case–control study , 2010, Scandinavian journal of gastroenterology.

[12]  B. Vásárhelyi,et al.  Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels. , 2010, Immunology letters.

[13]  Tadashi Yamamoto,et al.  Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. , 2010, American journal of physiology. Renal physiology.

[14]  G. Parks,et al.  Pivotal Advance: Nonfunctional lung effectors exhibit decreased calcium mobilization associated with reduced expression of ORAI1 , 2010, Journal of leukocyte biology.

[15]  H. Wulff,et al.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends , 2010, Expert review of clinical pharmacology.

[16]  H. Wulff,et al.  Inhibition of the K+ channel KCa3.1 ameliorates T cell–mediated colitis , 2010, Proceedings of the National Academy of Sciences.

[17]  K. Chandy,et al.  The functional network of ion channels in T lymphocytes , 2009, Immunological reviews.

[18]  Richard A Flavell,et al.  A protective function for interleukin 17A in T cell–mediated intestinal inflammation , 2009, Nature Immunology.

[19]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[20]  D. Tribble,et al.  Infectious gastroenteritis and risk of developing inflammatory bowel disease. , 2008, Gastroenterology.

[21]  A. Rao,et al.  Calcium signaling in lymphocytes. , 2008, Current opinion in immunology.

[22]  H. Wulff,et al.  Targeting effector memory T-cells with Kv1.3 blockers. , 2007, Current opinion in drug discovery & development.

[23]  S. Griffey,et al.  Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. , 2007, The Journal of investigative dermatology.

[24]  J. E. Matos,et al.  Role of cholinergic‐activated KCa1.1 (BK), KCa3.1 (SK4) and KV7.1 (KCNQ1) channels in mouse colonic Cl− secretion , 2007, Acta physiologica.

[25]  S. Griffey,et al.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases , 2006, Proceedings of the National Academy of Sciences.

[26]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[27]  L. Öhman,et al.  Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity , 2006, Inflammatory bowel diseases.

[28]  H. Wulff,et al.  Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases , 2005, Molecular Pharmacology.

[29]  S. Feske,et al.  A severe defect in CRAC Ca2+ channel activation and altered K+ channel gating in T cells from immunodeficient patients , 2005, The Journal of experimental medicine.

[30]  P. Calabresi,et al.  The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Zeitz,et al.  Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. , 2005, Gastroenterology.

[32]  C. Fiocchi,et al.  Inflammatory Bowel Disease: Autoimmune or Immune-mediated Pathogenesis? , 2004, Clinical & developmental immunology.

[33]  P. Mannon,et al.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. , 2004, The Journal of clinical investigation.

[34]  K. Nagata,et al.  Differential expression of CCR5 and CRTH2 on infiltrated cells in colonic mucosa of patients with ulcerative colitis , 2003, Journal of gastroenterology and hepatology.

[35]  E. Lindberg,et al.  Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. , 2003, Gastroenterology.

[36]  P. Calabresi,et al.  The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. , 2003, The Journal of clinical investigation.

[37]  J. Stocker,et al.  ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. , 2003, Blood.

[38]  B. Iizuka,et al.  Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis , 2002, American Journal of Gastroenterology.

[39]  K. Okita,et al.  Increased expression of tumor necrosis factor-α messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase , 2002, Journal of Gastroenterology.

[40]  S. McCulle,et al.  Vasoactive Intestinal Peptide-stimulated Cl?Secretion: Activation of cAMP-dependent K+ Channels , 2002, The Journal of Membrane Biology.

[41]  Mark J. Miller,et al.  Up-regulation of the IKCa1 Potassium Channel during T-cell Activation , 2000, The Journal of Biological Chemistry.

[42]  A. Schwab,et al.  Molecular and functional characterization of the small Ca2+-regulated K+ channel (rSK4) of colonic crypts , 1999, Pflügers Archiv.

[43]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.

[44]  M. Neurath,et al.  Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. , 1996, Journal of immunology.

[45]  A. Morgan,et al.  Ionomycin enhances Ca2+ influx by stimulating store-regulated cation entry and not by a direct action at the plasma membrane. , 1994, The Biochemical journal.

[46]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[47]  J. Heppell,et al.  Toxic megacolon , 1986, Diseases of the colon and rectum.

[48]  P. Calabresi,et al.  EncephalomyelitisMice Resistant to Autoimmune Immunoregulatory Phenotype and Renders Kv1.3 Deletion Biases T Cells toward an , 2012 .

[49]  J. Kinet,et al.  Molecular clustering of STIM1 with Orai1/CRACM1 at the plasma membrane depends dynamically on depletion of Ca2+ stores and on electrostatic interactions. , 2009, Molecular biology of the cell.

[50]  K. Ataga,et al.  Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. , 2009, Expert opinion on investigational drugs.

[51]  Christopher B Wilson,et al.  Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.

[52]  赤澤 哲子.  Increased expression of tumor necrosis factor-α messenger RNA in the intestinal mucosa of inflammatory bowel disease : Particularly in patients with disease in the inactive phase , 2002 .

[53]  T. Sørensen,et al.  Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. , 2000, Scandinavian journal of gastroenterology.

[54]  T. Wright,et al.  Cytokines in acute and chronic inflammation. , 1997, Frontiers in bioscience : a journal and virtual library.

[55]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[56]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[57]  Jay K Kolls,et al.  The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation , 2022 .